Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10720509 | 0.92 | L3MBTL1 (0.71) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL14786240 | 0.88 | ALDH1A1 (0.62) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL28294867 | 0.87 | HPGD (0.71) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL14508043 | 0.86 | HPGD (0.71) | MEN1KMT2AL3MBTL1HPGDTSHR | |
| SCHEMBL1199986 | 0.85 | L3MBTL1 (0.64) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL30577960 | 0.85 | L3MBTL1 (0.64) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL367502 | 0.85 | HPGD (0.65) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL30568869 | 0.84 | L3MBTL1 (0.62) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL520393 | 0.84 | L3MBTL1 (0.62) | MEN1KMT2AL3MBTL1HPGDKDM4E | |
| SCHEMBL3076585 | 0.84 | TSHR (0.67) | MEN1KMT2AL3MBTL1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| EP-2188289-A2 | (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | Lexicon Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | claimed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | claimed |
| WO-2009021169-A2 | (7H-PYRR0L0 [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | LEXICON PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| CN-116655595-A | 2, 6-piperidinedione derivatives, their preparation and use | 中国人民解放军军事科学院军事医学研究院 | 2023-08-29 | — | — | CN | disclosed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2188289-B1 | (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | LEXICON PHARMACEUTICALS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2597098-A1 | (7H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | MEN1 2881/4885KMT2A 2799/4885L3MBTL1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.